Chronic cocaine and heroin users display a variety of central nervous system (CNS) dysfunctions including impaired attention, learning, memory, reaction time, cognitive flexibility, impulse control and selective processing. These findings suggest that these drugs may alter normal brain functions and possibly cause neurotoxicity. Neurotrophins are a class of proteins that serve as survival factors for CNS neurons. In particular, nerve growth factor (NGF) plays an important role in the survival and function of cholinergic neurons while brain-derived neurotrophic factor (BDNF) is involved in synaptic plasticity and in the maintenance of midbrain dopaminergic and cholinergic neurons. In the present study, we measured by enzyme-linked immunosorbent assay (ELISA) the NGF and BDNF levels in serum of three groups of subjects: heroin-dependent patients, cocaine-dependent patients and healthy volunteers. Our goal was to identify possible change in serum neurotrophins in heroin and cocaine users. BDNF was decreased in heroin users whereas NGF was decreased in both heroin and cocaine users. These findings indicate that NGF and BDNF may play a role in the neurotoxicity and addiction induced by these drugs. In view of the neurotrophin hypothesis of schizophrenia the data also suggest that reduced level of neurotrophins may increase the risk of developing psychosis in drug users.
Angelucci F., Mathe A.A., Aloe L. ( 2004) Neurotrophic factors and CNS disorders: findings in rodent models of depression and schizophrenia. Prog Brain Res146: 151—165
2.
Bolla K.I., Funderburk F.R., Cadet J.L. (2000) Differential effects of cocaine and cocaine alcohol on neurocognitive performance. Neurology54: 2285—2292
3.
Browne S.E., Lin L., Mattsson A., Georgievska B., Isacson O. (2001) Selective antibody-induced cholinergic cell and synapse loss produce sustained hippocampal and cortical hypometabolism with correlated cognitive deficits. Exp Neurol170: 36—47
4.
Cantor-Graae E., Nordstrom L.G., McNeil T.F. (2001) Substance abuse in schizophrenia: a review of the literature and a study of correlates in Sweden. Schizophr Res48: 69—82
5.
Canudas A.M., Pezzi S., Canals J.M., Pallas M., Alberch J. (2005) Endogenous brain-derived neurotrophic factor protects dopaminergic nigral neurons against transneuronal degeneration induced by striatal excitotoxic injury. Brain Res Mol Brain Res134: 147—154
6.
Cheng C.Y., Hong C.J., Yu Y.W., Chen T.J., Wu H.C., Tsai S.J. (2005) Brain-derived neurotrophic factor (Val66Met) genetic polymorphism is associated with substance abuse in males. Brain Res Mol Brain Res140: 86—90
7.
Cipolli C., Galliani I. (1987) Addiction time and intellectual impairment in heroin users. Psychol Rep60: 1099—1105
8.
Connor B., Dragunow M. (1998) The role of neuronal growth factors in neurodegenerative disorders of the human brain. Brain Res Brain Res Rev27: 1—39
9.
Cunha A.B., Frey B.N., Andreazza A.C., Goi J.D., Rosa A.R., Goncalves C.A., Santin A., Kapczinski F. (2006) Serum brain-derived neurotrophic factor is decreased in bipolar disorder during depressive and manic episodes. Neurosci Lett398: 215—219
10.
Dalley J.W., Laane K., Pena Y., Theobald D.E., Everitt B.J., Robbins T.W. (2005) Attentional and motivational deficits in rats withdrawn from intravenous self-administration of cocaine or heroin. Psychopharmacology (Berl)182: 579—587
11.
Egan M.F., Kojima M., Callicott J.H., Goldberg T.E., Kolachana B.S., Bertolino A., Zaitsev E., Gold B., Goldman D., Dean M., Lu B., Weinberger D.R. (2003) The BDNF Val66Met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell112: 257—269
12.
Ettenberg A., MacConell L.A., Geist T.D. (1996) Effects of haloperidol in a response-reinstatement model of heroin relapse. Psychopharmacology124: 205—210
13.
Filip M., Faron-Gorecka A., Kusmider M., Golda A., Frankowska M., Dziedzicka-Wasylewska M. (2006) Alterations in BDNF and trkB mRNAs following acute or sensitizing cocaine treatments and withdrawal. Brain Res1071: 218—225
14.
Gervasoni N., Aubry J.M., Bondolfi G., Osiek C., Schwald M., Bertschy G., Karege F. (2005) Partial normalization of serum brain-derived neurotrophic factor in remitted patients after a major depressive episode. Neuropsychobiology51: 234—238
15.
Grimm J.W., Lu L., Hayashi T., Hope B.T., Su T.P., Shaham Y. (2003) Time-dependent increases in brain-derived neurotrophic factor protein levels within the mesolimbic dopamine system after withdrawal from cocaine: implications for incubation of cocaine craving. J Neurosci23: 742—747
16.
Guerra D., Sole A., Cami J., Tobena A. (1987) Neuropsychological performance in opiate addicts after rapid detoxification. Drug Alcohol Depend20: 261—270
17.
Ha D.H., Robertson R.T., Roshanaei M., Weiss J.H. (1999) Enhanced survival and morphological features of basal forebrain cholinergic neurons in vitro: role of neurotrophins and other potential cortically derived cholinergic trophic factors. J Comp Neurol406: 156—170
18.
Hester R., Garavan H. (2004) Executive dysfunction in cocaine addiction: evidence for discordant frontal, cingulate, and cerebellar activity. J Neurosci24: 11017—11022
19.
Huang T.L., Lee C.T. (2006) Associations between serum brain-derived neurotrophic factor levels and clinical phenotypes in schizophrenia patients. J Psychiatr Res40: 664—668
20.
Hyman C., Hofer M., Barde Y.A., Juhasz M., Yancopoulos G.D., Squinto S.P., Lindsay R.M. (1991) BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra. Nature350: 230—232
21.
Karege F., Perret G., Bondolfi G., Schwald M., Bertschy G., Aubry J.M. (2002a) Decreased serum brain-derived neurotrophic factor levels in major depressed patients. Psychiatr Res109: 143—148
22.
Karege F., Schwald M., Cisse M. (2002b) Postnatal developmental profile of brain-derived neurotrophic factor in rat brain and platelets. Neurosci Lett328: 261—264
23.
Kastin A.J., Pan W., Maness L.M., Banks W.A. (1999) Peptides crossing the blood-brain barrier: some unusual observations. Brain Res848: 96—100
24.
Kim D.J., Roh S., Kim Y., Yoon S.J., Lee H.K., Han C.S., Kim Y.K. (2005) High concentrations of plasma brain-derived neurotrophic factor in methamphetamine users. Neurosci Lett388: 112—115
25.
Klongpanichapak S., Govitrapong P., Sharma S.K., Ebadi M. (2006) Attenuation of cocaine and methamphetamine neurotoxicity by coenzyme Q10. Neurochem Res31: 303—311
26.
Lad S.P., Neet K.E., Mufson E.J. (2003) Nerve growth factor: structure, function and therapeutic implications for Alzheimer's disease. Curr Drug Targets CNS Neurol Disord2: 315—334
27.
Laske C., Stransky E., Leyhe T., Eschweiler G.W., Schott K., Langer H., Gawaz M. (2006) Decreased brain-derived neurotrophic factor (BDNF)- and betathromboglobulin (beta-TG)-blood levels in Alzheimer's disease. Thromb Haemost96: 102—103
28.
Le Foll B., Diaz J., Sokoloff P. (2005) A single cocaine exposure increases BDNF and D3 receptor expression: implications for drug-conditioning. Neuroreport16: 175—178
29.
Lundqvist T. (2005) Cognitive consequences of cannabis use: comparison with abuse of stimulants and heroin with regard to attention, memory and executive functions. Pharmacol Biochem Behav81: 319—330
30.
Maren S., Fanselow M.S. (1995) Synaptic plasticity in the basolateral amygdala induced by hippocampal formation stimulation in vivo. J Neurosci15: 7548—7564
31.
Meredith G.E., Callen S., Scheuer D.A. (2002) Brain-derived neurotrophic factor expression is increased in the rat amygdala, piriform cortex and hypothalamus following repeated amphetamine administration. Brain Res949: 218—227
32.
Meshul C.K., Noguchi K., Emre N., Ellison G. (1998) Cocaine-induced changes in glutamate and GABA immunolabeling within rat habenula and nucleus accumbens. Synapse2: 211—220
33.
Norman A.B., Norman M.K., Hall J.F., Tsibulsky V.L. (1999) Priming threshold: a novel quantitative measure of the reinstatement of cocaine self-administration. Brain Res831: 165—174
34.
Olsen G.D. (1995) Potential mechanisms of cocaine-induced developmental neurotoxicity: a minireview. Neurotoxicology16: 159—167
35.
Pan W., Banks W.A., Fasold M.B., Bluth J., Kastin A.J. (1998) Transport of brain-derived neurotrophic factor across the blood-brain barrier. Neuropharmacology37: 1553—1561
36.
Parikh V., Evans D.R., Khan M.M., Mahadik S.P. (2003) Nerve growth factor in never-medicated first-episode psychotic and medicated chronic schizophrenic patients: possible implications for treatment outcome. Schizophr Res60: 117—123
37.
Pierce R., Bari A. ( 2001) The role of neurotrophic factors in psychostimulant-induced behavioral and neuronal plasticity. Rev Neurosci12: 95—110
38.
Regier D.A., Farmer M.E., Rae D.S., Locke B.Z., Keith S.J., Judd L.L., Goodwin F.K. (1990) Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study . JAMA264: 2511—2518
39.
Schlaepfer T., Lancaster E., Heidbreder R., Strain E., Kosel M., Fisch H., Pearlson G. (2006) Decreased frontal white-matter volume in chronic substance abuse. Int J Neuropsychopharmacol2: 147—153
40.
Shaham Y., Stewart J. (1996) Effects of opioid and dopamine receptor antagonists on relapse induced by stress and reexposure to heroin in rats. Psychopharmacology125: 385—391
41.
Shimizu E., Hashimoto K., Watanabe H., Komatsu N., Okamura N., Koike K., Shinoda N., Nakazato M., Kumakiri C., Okada S., Iyo M. ( 2003) Serum brain-derived neurotrophic factor (BDNF) levels in schizophrenia are indistinguishable from controls. Neurosci Lett351: 111—114
42.
Spain J.W., Newsom G.C. (1991) Chronic opioids impair acquisition of both radial maze and Y-maze choice escape. Psychopharmacology (Berl)105: 101—106
43.
Tan Y.L., Zhou D.F., Cao L.Y., Zou Y.Z., Zhang X.Y. (2005) Decreased BDNF in serum of patients with chronic schizophrenia on long-term treatment with antipsychotics. Neurosci Lett382: 27—32
44.
Thirthalli J., Benegal V. (2006) Psychosis among substance users. Curr Opin Psychiatr19: 239—245
45.
Thoenen H. (1995) Neurotrophins and neuronal plasticity. Science270: 593—598
46.
Toyooka K., Asama K., Watanabe Y., Muratake T., Takahashi M., Someya T., Nawa H. ( 2002) Decreased levels of brain-derived neurotrophic factor in serum of chronic schizophrenic patients. Psychiatr Res110: 249—257
47.
van den Brink W., van Ree J. (2003) Pharmacological treatments for heroin and cocaine addiction. Eur Neuropsychopharmacol13: 476—487
48.
Wise R. ( 1996) Neurobiology of addiction. Curr Opin Neurobiol6: 243—251
49.
Yasutake C., Kuroda K., Yanagawa T., Okamura T., Yoneda H. (2006) Serum BDNF, TNF-alpha and IL-1beta levels in dementia patients: Comparison between Alzheimer's disease and vascular dementia. Eur Arch Psychiatry Clin Neurosci256: 402—406
50.
Zanardini R., Gazzoli A., Ventriglia M., Perez J., Bignotti S., Rossini P.M., Gennarelli M., Bocchio-Chiavetto L. (2006) Effect of repetitive transcranial magnetic stimulation on serum brain derived neurotrophic factor in drug resistant depressed patients . J Affect Disord91: 83—86
